who survived AR gained full neurologic recovery. No aortoiliac injury or limb loss occurred from REBOA use per se but rather from severe preplacement extremity injury. Eleven patients underwent REBOA for NTH; 7 (64%) were in arrest. Overall in-hospital mortality for patients with NTH was 36% (n ¼ 4). Only patient died of bowel necrosis after an inflation time of longer than 2 hours. No procedural complications occurred in this group but at the time of removal three access site repairs were required in addition to 9 patients who required thrombectomy, 6 of whom were cannulated with 12 French sheaths.
Comments: Others are learning from our experience with the care of a ruptured abdominal aortic aneurysm. This experience confirms in another cohort of patients the utility of aortic balloon occlusion for control of significant abdominal arterial bleeding with some risk of malposition without immediate imaging. Access site repair or extremity thrombectomy is not uncommon, may be the price for a survival advantage, but most be considered to prevent delayed morbidity or mortality. Conclusions: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo.
Effects of Anacetrapib in Patients With
Summary: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or even adverse effects on cardiovascular outcomes. In this industrial sponsored randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter, a mean non-HDL cholesterol level of 92 mg per deciliter, and a mean HDL cholesterol level of 40 mg per deciliter. The authors have classified it as the phase 3 Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification (REVEAL) trial. Routine follow-up was at 2 months than 6 months until study's end. The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. Secondary outcomes were major atherosclerotic events (a composite of coronary death, myocardial infarction, or presumed ischemic stroke), presumed ischemic stroke (ie, not known to be hemorrhagic), and major vascular events (a composite of major coronary events or presumed ischemic stroke). During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P ¼ 0.004). The relative difference in risk was similar across multiple pre-specified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (a relative difference of À18%).The only secondary outcome not statistically different was the effect of anacetrapib on presumed ischemic stroke (rate ratio, 0.99; 95% confidence interval, 0.87-1.12).There were no significant between group differences in the risk of death, cancer, or other serious adverse events.
Comments: Aggressive lowering of LDL serum levels has an incremental reduction in the risk of major cardiovascular events which appears to be augmented by the use of this particular CETP inhibitor. Several other studies of similar drugs have either been stopped early or did not improve the prevention rate of cardiovascular events over time. The authors' feel that this study differs in terms of the number of patients involved, stringent LDL level maintenance and length of treatment in addition to the specific attributes of anacetrapib. Fortunately, side-effects of this agent do not appear substantial but since it is stored in adipose tissues (with slow egress) the longer term side effects may yet to be determined. Conclusions: Hospital participation in the VQI registry by itself does not increase rates of surveillance imaging after vascular procedures, suggesting that other strategies are needed to achieve this quality metric.
Association of Quality Improvement Registry
Summary: Ensuring that patients undergo surveillance imaging after surgery is a key to improving long term results after many vascular procedures. It is unclear whether hospital participation in a national quality improvement registry such as the Vascular Quality Initiative (VQI) achieves this goal. This study was undertaken to determine if hospital participation in the VQI registry is associated with increased rates of surveillance imaging after vascular procedures. A quasi-experimental study used Medicare claims to study 2174 US hospitals in which 1,530,102 patients had undergone an endovascular abdominal aortic aneurysm repair (EVAR); 1,403,067 patients had undergone a lower extremity bypass (LEB) or peripheral vascular intervention (PVI), and 294,942 patients had undergone carotid endarterectomy (CEA) and carotid artery stenting (CAS) procedures over a 6 year period ending in 2012. For each hospital, VQI participation was assessed, and a difference-in-differences analysis was used to measure the change in follow-up surveillance for VQI hospitals compared with control (non-VQI) hospitals selected after propensity score matching. The data were analyzed between January and August of 2016. The primary outcome was the proportion of patients who had imaging-based follow-up (computed tomography, duplex ultrasonography, or ankle-brachial index) within 1 year after their vascular procedure. A total of 1,830 928 patients (947,139 women and 883,789 men; mean age (standard deviation [SD]) 75.8 [7.1] years) were identified across 2174 hospitals. Of 3,228,111 total vascular procedures, 1,403,067 patients (43.5%) underwent LEB or PVI, 1,530,102 patients (47.4%) underwent EVAR, and 294,942 patients (9.1%) underwent CEA or CAS. During the 6-year period, follow-up imaging rates varied between 50% and 53% after EVAR, between 52%and 58% after LEB or PVI, and between 74%and 78% after CEA or CAS. A total of 68 VQI participating hospitals were propensity-matched to 68 control hospitals, and 279.446 patients were studied across these 136 hospitals. In difference-in-differences analyses, there was no significant improvement in follow-up imaging after joining VQI during year 1 (relative risk, 0.99; 95% confidence interval [CI], 0.97-1.01),
